SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology ...
Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience SAN ...
Illumina, Inc. is further extending the reach of the NextSeq 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a ...
NextSeq 1000 and 2000 systems are redesigned from the ground up to maximize future proofing, offering sequencing power for high throughput applications. Offering scalability for evolving needs and ...
Illumina CEO Francis deSouza on Monday unveiled two new sequencing systems, NextSeq 2000 (pictured) and NextSeq 1000, both designed to meet growing demand for clinical genomic data at reduced cost, as ...
KUALA LUMPUR, Nov 13 -- Illumina Inc is further extending the reach of the NextSeq™ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 ...
The Bristol Genomics Facility offers next-generation sequencing on the NextSeq 2000, one of the newest high-throughput sequencing instruments made by Illumina. The Illumina NextSeq 2000 is a very ...
The NextSeq 1000 and NextSeq 2000 Systems are thoughtfully designed to enable more insights on your benchtop. With 14 configurations and read lengths from 1 × 50bp to 2 × 300bp, these systems ...
Now Commercially Available, Both NextSeq 1000 and NextSeq 2000 Sequencers Include Integrated Informatics and Loss-less Compression Technology, Creating an Intuitive User Experience Now commercially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results